Myeloproliferative Neoplasms News

The addition of pevonedistat to azacitidine for first-line treatment of certain patients with blood cancers failed to extend EFS, according to topline data released by the agent’s manufacturer.

Lachelle Dawn Weeks, MD, PhD, of Dana-Farber Cancer Institute and Emilio Ramos, MD, PhD, of University of California, San Francisco, received the ASH-Harold Amos Medical Faculty Development Program Award.

A free nurse navigation service helped overcome barriers to clinical trial enrollment for patients with blood cancer, according to study results published in JCO Oncology Practice.

The FDA placed a clinical hold on a phase 3 study designed to evaluate elivaldogene autotemcel, an investigational gene therapy, for the treatment of younger patients with cerebral adrenoleukodystrophy.

Approximately one-quarter of patients with hematologic malignancies did not produce measurable antibodies after two doses of COVID-19 vaccines, according to a study from The Leukemia & Lymphoma Society published in Cancer Cell.

The COVID-19 pandemic has underscored the importance of vaccination, both in terms of protecting individuals from infection and eradicating threats to public health.

The FDA granted breakthrough therapy designation to venetoclax in combination with azacitidine for treatment of certain patients with myelodysplastic syndrome.

In this episode, Julie Rubinstein, MBA, discusses her journey into the cancer space, the importance of personalized medicine and how her father’s cancer diagnosis played a role in her career.

Convalescent plasma treatment appeared associated with a reduction in 30-day mortality among patients with hematologic malignancies hospitalized for COVID-19, according to study results published in JAMA Oncology.

The FDA granted priority review to pacritinib for treatment of patients with myelofibrosis with severe thrombocytopenia, according to the agent’s manufacturer.